- Home
- ZURA vs PRQR Comparison
ZURA vs PRQR Comparison
Compare ZURA & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | PRQR |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 262.5M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZURA | PRQR |
|---|---|---|
| Price | $5.25 | $1.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $13.00 | $7.25 |
| AVG Volume (30 Days) | ★ 1.6M | 865.6K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.88 | $1.33 |
| 52 Week High | $7.25 | $3.10 |
Technical Indicators
Market Signals| Indicator | ZURA | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 41.00 |
| Support Level | $5.22 | $1.91 |
| Resistance Level | $5.87 | $1.99 |
| Average True Range (ATR) | 0.43 | 0.12 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 3.54 | 0.92 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.